Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life

J Clin Endocrinol Metab. 2005 May;90(5):2731-9. doi: 10.1210/jc.2004-2297. Epub 2005 Mar 1.

Abstract

Active acromegaly is associated with significant comorbidity and reduced quality of life. However, the prevalence of comorbidity after long-term remission is not established. Therefore, we assessed the presence of comorbidity in 118 patients in long-term remission after surgery, radiotherapy, and/or somatostatin analog treatment according to strict biochemical criteria of serum GH and IGF-I concentrations and evaluated the impact of comorbidity on quality of life. The mean duration of remission was 12.0 +/- 7.4 yr, and mean actual IGF-I sd scores were 0.6 +/- 1.7. Self-reported joint problems occurred in 77% of patients, hypertension in 37%, a history of myocardial infarction in 9%, and diabetes mellitus in 11%. The presence of joint problems was not related to GH and IGF-I levels, active disease duration, or age. Joint complaints had significant negative impact on quality of life. Patients with a history of myocardial infarction had reduced scores for general health, depression, and fatigue, and diabetes mellitus was associated with reduced scores for anxiety and sleep. In conclusion, acromegalic patients had a high prevalence of joint-related comorbidity and hypertension despite long-term control of GH excess. Especially, joint complaints contributed to a reduced perceived quality of life in these patients.

MeSH terms

  • Acromegaly / complications*
  • Acromegaly / psychology
  • Adult
  • Aged
  • Diabetes Mellitus / epidemiology
  • Female
  • Humans
  • Hypertension / epidemiology
  • Joint Diseases / epidemiology
  • Joint Diseases / psychology*
  • Male
  • Middle Aged
  • Morbidity
  • Osteoarthritis / epidemiology
  • Prevalence
  • Quality of Life*